EP Patent

EP1856087A1 — Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamine oxalate and the preparation thereof

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2007-11-21 · 18y expired

What this patent protects

DNT-Oxal crystalline forms and processes for making DNT-Oxal crystalline forms are provided. DNT-Oxal refering to the compound (S) -(+) -N, N -dimethyl -3-(1- naphlthalenyloxy)-3-(2-thienyl) -propanamine oxalate .

USPTO Abstract

DNT-Oxal crystalline forms and processes for making DNT-Oxal crystalline forms are provided. DNT-Oxal refering to the compound (S) -(+) -N, N -dimethyl -3-(1- naphlthalenyloxy)-3-(2-thienyl) -propanamine oxalate .

Drugs covered by this patent

Patent Metadata

Patent number
EP1856087A1
Jurisdiction
EP
Classification
—
Expires
2007-11-21
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.